UPB — Upstream Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2022626 ·
Last close
$8.21
Market Cap
$446.79M
52W High
$10.67
52W Low
$7.25
ADV30
558,186
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,034,000 | — | -43,615,000 | -40,591,000 | 318,054,000 | 96,724,000 | 14,059,000 |
| Dec 2025 | 668,000 | — | -46,167,000 | -42,459,000 | 353,772,000 | 101,578,000 | 14,001,000 |
| Sep 2025 | 683,000 | — | -37,834,000 | -33,748,000 | 391,195,000 | 72,164,000 | 12,611,000 |
| Jun 2025 | 937,000 | — | -44,347,000 | -39,966,000 | 420,521,000 | 45,458,000 | 11,778,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-133,275,000
Investing CF
$-93,480,000
Financing CF
$2,441,000
CapEx
$-303,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.66
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,223,000
Inventory
—
Receivables
$2,321,000
ST Investments
$239,931,000
EBIT TTM
$-160,361,000
Pretax Income TTM
$-143,443,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,322,000
EBITDA
$-171,768,992
Free Cash Flow
$-90,310,872
Enterprise Value
$162,030,288
Total Cash
$294,579,008
Total Debt
$1,114,000
Shares Out
54,419,986
Trailing EPS
$-2.91
Book Value
$6.26
ROE
-41.8%
ROA
-27.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,854,000 | -160,361,000 | -143,443,000 | 353,772,000 | 14,001,000 | — | -133,275,000 |
| Dec 2024 | 2,370,000 | -77,764,000 | -62,806,000 | 481,719,000 | 11,867,000 | — | -59,172,000 |
| Dec 2023 | 2,380,000 | -40,114,000 | -20,537,000 | 117,198,000 | 240,324,000 | — | -37,926,000 |
| Dec 2022 | 1,212,000 | -23,909,000 | -23,868,000 | 18,478,000 | 124,633,000 | — | -19,021,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.02
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $8.21 · call volume: 142 · put volume: 15
Expected Move to 2026-08-21:
±$3.06
(37.27%) —
implied range
$5.15 –
$11.27
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | $446.44M | $3.51 | — |
| CTNM | Contineum Therapeutics, Inc. | $448.32M | $13.70 | — |
| FBRX | Forte Biosciences, Inc. | $449.31M | $21.94 | — |
| FULC | Fulcrum Therapeutics, Inc. | $450.44M | $6.76 | — |
| SGMT | Sagimet Biosciences Inc. | $441.75M | $7.22 | — |
News headlines (Yahoo Finance, 1h cache)
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International
2026-05-18 15:30 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 12:20 · Yahoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:00 · Yahoo
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
2026-04-17 11:00 · Yahoo
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
2026-03-27 13:46 · Yahoo
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
2026-03-27 12:04 · Yahoo
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-26 11:00 · Yahoo
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
2026-03-05 22:31 · Yahoo
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
2026-03-01 14:45 · Yahoo
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
2026-02-26 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.